Research

*August 2021* In this video, Dr. David Carbone talked about the promise and successes of targeted therapies and immunotherapy, answered questions about oncogene mutations and available treatments, and outlined current studies that could be game-changers for lung cancer patients. Watch the video here.

*August 2021* Introduction Management of central nervous system (CNS) metastases in patients with driver-mutated NSCLC has traditionally incorporated both tyrosine kinase inhibitors (TKIs) and intracranial radiation. Whether next generation, CNS-penetrant TKIs can be used alone without upfront radiation, however, remains unknown. This multi-institutional retrospective analysis aimed to compare outcomes in…

*July 2021* Note: Although the use of immunotherapy can be questionable in EGFR+ lung cancer, resistance to immunotherapy might be of interest anyway. Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and is usually not diagnosed until an advanced-stage disease is present. Chemotherapy is the…

*May 2021* Note: Is further evaluation of the combination warranted for patients with locally advanced or metastatic T790M-negative, EGFR-positive NSCLC? The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor mutation (EFGR) mutation…

*July 2021* Note  Should a VEGF inhibitor (bevacizumab/Avastin) be combined with osimertinib or not? The role of osimertinib combinations as second-line treatment for advanced non-small cell lung cancer (NSCLC) is still unclear, according to researchers. Osimertinib is a standard first-line treatment option for patients with advanced NSCLC and EGFR mutations, but progression on this…

*July 2021* Patritumab deruxtecan (HER3-DXd), an antibody drug conjugate consisting of a fully human monoclonal antibody to HER3 attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker, achieved clinically meaningful, durable efficacy in a phase I dose escalation and dose expansion study conducted in patients with locally…

*July 2021* Combination targeting of epidermal growth factor receptor (EGFR) with amivantamab/lazertinib achieved durable responses in more than one-third of chemotherapy-naive patients with EGFR-mutant non–small cell lung cancer (NSCLC) that had progressed on osimertinib, according to a cohort analysis of the CHRYSALIS trial presented at the 2021 ASCO Annual Meeting.1 The study…

*July 2021* As research efforts prevail with encouraging therapies designed to overcome resistance to EGFR-directed therapies for patients with advanced non–small cell lung cancer (NSCLC), Sukhmani K. Padda, MD, noted that hope indeed exists for this patient populations. “There may be strategies after a certain resistance that are going to…

*July 2021* Osimertinib (Tagrisso) has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer (NSCLC), but the need for novel agents is underscored as disease progression on the agent is inevitable, according to Karen Kelly, MD. To this end, bispecific antibodies, antibody-drug conjugates (ADCs), EGF…

*July 2021* Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) in the first line setting are the key to unlocking the next wave of success in treating lung cancer, according to Jonathan W. Riess, MD, MS, associate professor of medicine at the University…